Articles related to CHRONIC MYELOID LEUKEMIA (CML)

Explore a compelling case study demonstrating the intricate relationship between chronic myeloid leukemia, autoimmunity, and post-transplant hematologic complications, highlighting the importance of thorough diagnostics and tailored treatment approaches in managing complex patient scenarios.

Explore the CML SUN study’s findings, which highlight the unmet need for shared decision-making in the choice of CML treatment—a void that may have an impact on patient satisfaction and treatment outcomes.

This study demonstrates how pharmacists can improve patient safety and dramatically save costs in the management of chronic myeloid leukemia by highlighting the possibility of pharmacist-led TKI cessation programs.

In this Q&A with Dr. Jorge Cortes, the Director of the Georgia Cancer Center, the drug asciminib is discussed based on its utility as a third-generation TKI as well as its favorable, unique characteristics. Early data has shown promising results with few adverse events, possibly illuminating the drug as a potential first-in-class agent.